首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到19条相似文献,搜索用时 109 毫秒
1.
磁导向下磁性化疗药物脑内定位分布的实验研究   总被引:1,自引:0,他引:1  
目的研究磁导向下磁性药物载体在脑内定位分布的特性,探讨恶性脑肿瘤的磁导向化疗的新途径. 方法90只SD大鼠随机分为3组:①磁导向组(n=30):将合成的磁微球-白蛋白-甲氨蝶呤载体(FM-HSA-MTX)混悬液,经尾静脉注入体内,右侧大脑外置一梯度磁场;②非磁导向组(n=30):只注入混悬液,无外置磁场;③对照组(n=30):注入甲氨蝶呤25 mg/kg,外置磁场.3组分别在给药后15、30、45 min随机取10只处死,测量甲氨蝶呤(MTX)在大鼠左右大脑内的含量.结果注药后15 min时,磁导向组导向侧(右侧)大脑MTX含量显著高于非磁导向组和对照组(磁导向组0.285±0.025 mg/g;非磁导向组0.103±0.018 mg/g;对照组0.137±0.024 mg/g,q磁导向组-非磁导向组=25.527,P<0.05;q磁导向组-对照组=20.758,P<0.05),对照组高于非磁导向组(q非磁导向组-对照组=4.769,P<0.05);30、45 min时磁导向组高于非磁导向组和对照组,非磁导向组与对照间无显著差异.给药后磁导向组大脑MTX含量升高,45 min时达最高(0.564±0.018 mg/g,q15-45=32.252,P<0.05),而非磁导向组和对照组导向侧大脑内MTX含量给药后45 min时含量较前下降(非磁导向组0.060±0.015 mg/g,q15-45=9.245,P<0.05,对照组0.074±0.045 mg/g,q15-45=6.299,P<0.05).给药后45 min,磁导向组导向侧大脑内MTX含量较左侧明显高(t45 min=21.135,P =0.000);非磁导向组与对照组左右两侧脑内MTX含量无显著性差异(非磁导向组:t45 min=0.434,P=0.670;对照组:t45 min=0.533,P=0.600). 结论磁性药物载体在磁导向下能在大脑靶部位定位分布.  相似文献   

2.
磁导向下磁性药物载体脑定位分布的研究   总被引:4,自引:0,他引:4  
目的 探讨磁导向下磁性药物载体脑定位分布特性及恶性脑肿瘤的磁导向化疗新途径。方法 将合成的磁微球-白蛋白-氨甲喋呤载体(FM-HAS-MTX)经尾静脉注入30只SD大鼠循环内,在大脑右侧放置1个梯度磁场,观察不同时间(15、30、45min)时氨甲喋呤(MTX)在SD大鼠大脑的分布善以及相同时间内左右大脑内MTX含量比较,同时研究磁导向与非磁导向时脑内MTX含量变化。结果 45min时磁迪蜃橛也啻  相似文献   

3.
磁性药物载体脑定向分布对肝肾及骨髓的影响   总被引:4,自引:0,他引:4  
目的 研究磁导向下磁性药物载体脑定向分布 ,磁性药物载体对肝、肾及骨髓的毒副作用 ,为脑胶质瘤的磁导向化疗提供可靠的依据。方法 昆明小鼠 5 0只 ,将一定量的磁性药物载体混悬液通过尾静脉注入小鼠体内 ,头部一侧放置聚焦磁场 ,定期给药观察 3个月 ,定时取血检查红细胞、白细胞、血小板、谷丙转氨酶 (ALT)、非蛋白氮 (NPN) ,并设立对照组。结果  7、14d磁导向组红细胞为(935 .0± 79.2 )、(92 5 .0± 81.5 )万 /mm3 ,肝功能及肾功能的变化不大 ,非磁导向组 (MTX组 )红细胞为(5 70 .0± 82 .2 )、(5 0 5 .0± 81.2 )万 /mm3 ,肝功能及肾功能的变化较大 ,两者差异有非常显著性(P <0 .0 1)。结论 磁导向下磁性药物载体定向分布于大脑靶区 ,改变了MTX随血流分布的特性 ,MTX在大脑定向浓集 ,而在肝、肾及骨髓的蓄积明显减少 ,显著减轻了对肝、肾及骨髓的损害作用。  相似文献   

4.
本实验检测白藜芦醇单用及与化疗药物合用对体外培养鼠肝癌细胞株H2 2(腹腔接种传代 )生长的影响 ,现将结果报道如下。一、材料和方法1.材料 :白藜芦醇购自Sigma公司(用二甲基亚酚溶解 ) ;小鼠肝癌H2 2细胞由本校免疫病理教研室提供 ,在含10 %小牛血清RPMI 164 0 (购于Gibco公司 )中培养 ;76只BALB/C小鼠 (购于西安交通大学医学院实验动物中心 )雌雄兼用 ;体重 (2 0± 2 ) g。 5 Fu购于西安交通大学第一医院西药房。2 .方法 :(1)将肝癌细胞H2 2细胞数(2× 10 4/孔 )接种在 96孔培养板上 ,在5 %CO2 、3 7.0℃培养箱中温育 12h后 ,分…  相似文献   

5.
低频超声对万古霉素骨水泥药物释放的影响   总被引:5,自引:1,他引:5  
目的在体外和动物体内条件下研究低频超声对抗生素骨水泥(antibiotic-loaded bone cement,ALBC)的促释放作用及其规律.方法制作载万古霉素ALBC的体外试件和体内试件.分别将质量分数为5%和10%的ALBC体外试件随机分为对照组、100mW/cm^2超声组和300mW/cm^2超声组.所有试件于40 ml PBS中浸泡8 h后,超声组接受超声干预30 min,观察浸泡24 h内药物累积浓度的变化.另取健康新西兰大白兔16只,将质量分数为7.5%的ALBC植入髋关节后随机分为对照组和超声组,每组8只.超声组于术后不同时间接受超声干预30min(300mW/cm^2),术后5 d内定时检测引流液和尿液中万古霉素浓度,术后4周检测ALBC残余药量.结果体外条件下100mW/cm^2超声组和1000 mW/cm^2超声组在浸泡24 h后的药物释放分别较10%对照组增加71.77%、73.62%,50mW/cm^2超声组和500 mW/cm^2超声组分别较5%对照组增加13.03%、23.78%.超声强度和药物载荷均显著增加ALBC的药物释放.体内条件下超声组药物释放量在术后1 d和5 d分别较对照组高148.18%(t=3.510,P<0.01)和82.39%(t=2.345,P<0.05),术后4周超声组ALBC药物溶出低于对照组(t=3.697,P<0.01).结论低频连续型超声能促进和加快ALBC的药物释放.  相似文献   

6.
纳米及微米磁微粒磁性顺铂微球对肝癌细胞的影响及机理   总被引:6,自引:2,他引:6  
目的 探讨用纳米及微米氧化铁磁核合成的磁性顺铂微球对人肝癌细胞BEL 740 2的影响及机理。方法 在肝癌细胞培养液中分别加入 0 .0 4~ 8μg/ml(按顺铂的含量计 )的顺铂 (CDDP)及含相应CDDP剂量的纳米磁微粒磁性顺铂微球 (nCDDPmm )和微米磁微粒磁性顺铂微球 (mCDDP mm ) ,并将 0 μg/mlCDDP与未包裹CDDP的磁性微球作为对照 ,采用MTT法、细胞计数法、流式细胞仪等观察肝癌细胞的活细胞数、杀伤率、生长曲线、细胞周期、增殖指数以及凋亡。结果  (1)随药物的浓度增加 ,肝癌细胞的活细胞数下降 ,杀伤率增加 ,呈明显的量效关系 (r值分别是 0 .95 ,0 .91,0 .89 ,P <0 .0 1) ;(2 )随药物的浓度增加 ,时间延长 ,肝癌细胞的生长曲线变低平 ,6~ 2 4h ,≤ 0 .8μg/ml时 ,nCDDPmm和mCDDPmm的细胞数高于CDDP (P <0 .0 5 ) ,nCDDPmm与mCDDPmm无明显差异(P >0 .0 5 ) ;(3 )随药物的浓度增加 ,肝癌细胞的凋亡率增加 ,nCDDPmm组的凋亡率高于mCDDPmm和CDDP组 (P <0 .0 1) ;(4 )CDDP ,nCDDPmm ,mCDDPmm均使肝癌细胞G0 /G1 期增加 ,S期及PI降低。结论 纳米及微米磁微粒磁性顺铂微球的抗肝癌细胞增殖作用取决于CDDP的浓度 ,其机理主要是诱导肝癌细胞凋亡。纳米磁微粒与微米磁微粒均有微弱促肝癌细胞增殖作用 ,但随作用  相似文献   

7.
肾细胞癌对化疗药物的多种耐药机制及其逆转   总被引:8,自引:0,他引:8  
多药耐药(MDR)是指某种细胞毒药物的耐药细胞系对许多结构上无关的和作用机制完全不同的其他抗癌药物产生交叉抗药性。MDR分两种类型:(1)天然耐药,即第一次化疗就产生耐药;(2)获得性耐药,即在化疗过程中产生耐药。肿瘤细胞一般对天然植物碱类和抗生素类...  相似文献   

8.
贫血对胃肠肿瘤化疗药物敏感性的影响   总被引:5,自引:0,他引:5  
2001年1月至2004年2月间,作者共收治经手术切除及病理确诊胃癌218例和大肠癌病人271例,其中胃癌伴发贫血78例,大肠癌伴发贫血65例。通过MTT法试验,对新鲜肿瘤标本进行肿瘤细胞的化疗药物敏感性检测,探讨胃癌、大肠癌伴发不同程度贫血时,肿瘤细胞对化疗药物敏感性的差异,以指导这类病人的临床化疗。  相似文献   

9.
目的 研究进展期胃癌术前给予阿霉素磁液靶向化疗后,胃癌组织中细胞凋亡与增殖状态的变化。方法 随机选择30例进展期胃癌,术前2周给予阿霉素磁液靶向化疗,应用脱氧核糖核酸末端转移酶介导的dUTP缺口末端标记法(TUNEL法)和增殖细胞核抗原(PCNA)免疫组织化学染色法,分别检测化疗前后胃癌组织及癌周正常粘膜组织中细胞凋亡指数(AI)与增殖细胞核抗原的指数(PI)。结果 术前阿霉素磁液化疗对正常粘膜组  相似文献   

10.
贺春英 《中国美容医学》2012,21(10):383-384
目的:调查实习护士对对化疗药物认知的现状,分析原因,提出对策,以便更好的实施临床护士的管理和代教。方法:采用问卷调查对218名临床实习护士对化疗药物的正确操作、副作用、正确防护等进行调查。结果:在化疗药物药理知识中;只有10.5%的护士对化疗药物的作用、副作用、用法很了解。在配置化疗药物过程中;只有16.1%的护士对应如何正确配置,如何做好自我防护很了解。在化疗药物污染方面;只有11.5%的护士对化疗药物污染皮肤、眼睛的应急措施比较了解。在个人防护方面;只有17.4%的护士对使用生物安全柜、带手套、带防护罩等防护措施很了解。结论:实习护士对化疗药的认知不足,在进入临床实习期间要进行系统化的肿瘤专科的培训,要加强对护士的针对性教育,提高实习护士的职业安全意识和水平,防止发生职业性暴露。  相似文献   

11.
目的选择Fe3O4与活性碳恰当配比(ζ/g)的混合原料,制备出铁碳复合磁性载体,用于肿瘤的磁靶向治疗。方法采用不同混合配比的Fe3O4和活性碳球磨配料,辅以表面包硅技术,合成出纳米纯铁和活性碳为主要组分的新型铁碳复合磁性载体,观察其粒子形貌与分布、磁性能及对阿霉素的吸附和脱附作用。结果合成的不同组分铁碳复合磁性载体颗粒直径均小于500 nm;包硅铁碳复合磁性载体性能稳定;Fe3O4和活性碳的混合配比为90/10(ζ/g)时,包硅铁碳复合磁性载体磁性能最强、吸附性能最弱;混合配比为60/40(ζ/g)时,包硅铁碳复合磁性载体对阿霉素的吸附性能最强、磁性能最弱。结论Fe3O4和活性碳的混合配比为70/30(ζ/g)时,合成的包硅铁碳复合磁性载体具有较强的磁性和恰当的吸附脱附性能,适合作为药物载体用于肿瘤的磁靶向治疗。  相似文献   

12.
目的选择一种最佳铁碳复合磁性材料作为药物载体。用于肿瘤的磁靶向治疗。方法活性碳与纳米Fe3O4按9:1(Wt/Wt)球磨制成初级铁碳复合磁性材料,采用不同的表面包附技术及氢气还原制备出两种铁碳复合磁性载体,分别测定其粒子形貌与分布、磁性能、对阿霉素的吸附和脱附作用。结果合成的两种磁性载体为铁碳复合颗粒表面分别包附SiO2及碳,颗粒直径均小于500nm;与包硅铁碳复合磁性载体相比,包碳铁碳复合磁性载体粒径较均匀(200~300)nm、磁饱和磁化强度较强(147emu/g89.9emu/g)及最大载药量较高(每克载体吸附阿霉素233.8mg:163.2mg)。结论包碳纳米铁碳复合磁性载体颗粒细小均匀、磁靶向性能强、载药量大并具有缓释功能,更适合作为磁性药物载体用于肿瘤的靶向治疗。  相似文献   

13.
目的 探讨采用含淤胆血清的培养体系直接从体外全骨髓细胞培养中筛选、扩增和分化骨髓源性肝干细胞的可行性.方法 制备含不同浓度淤胆血清的条件筛选培养液,常规培养大鼠全骨髓细胞,贴壁后换用条件筛选培养液,根据筛选的结果确定最佳的淤胆血清浓度.筛选到的骨髓源性肝干细胞分别采用扩增培养液和分化培养液进行扩增和诱导分化.传代细胞应用流式细胞仪检测干细胞标记.采用免疫组织化学、RT-PCR和电镜等方法对骨髓源性肝干细胞进行形态学以及表型特征的鉴定.以糖原染色和尿素分析的方法对诱导分化的细胞进行代谢功能的测定.结果 筛选培养结果,含50 ml/L的淤胆血清培养液的筛选效果最佳:骨髓源性肝干细胞能够生存,而其他非肝干细胞因不能适应而凋亡.纯化的肝干细胞能在扩增培养体系中传代6代并且维持稳定的细胞表面特征.更换为分化培养体系后,可形成肝细胞样集落形成单位.肝细胞样集落形成单位的细胞表达胎肝细胞的标志(AFP,白蛋白和细胞角蛋白8/18),胆管细胞的标志(细胞角蛋白19),肝细胞的功能蛋白(甲状腺素转运蛋白和细胞色素P450-2 b1),以及肝细胞核因子(HNF-1α和HNF-3 β).同时具有糖原储存和尿素合成等肝细胞特有功能.结论 含淤胆血清的筛选培养液能从全骨髓细胞培养中有效地筛选骨髓源性肝干细胞,并且纯化的肝干细胞能传代6代.肝干细胞分化后能形成具有肝细胞样的表型和功能.骨髓源性肝干细胞为解决临床肝细胞治疗的肝细胞来源问题提供了一个新的方法.  相似文献   

14.
Objective To explore the feasibility of direct separation, selective proliferation and differentiation of BDLSC from hone marrow cells with culture systems containing cholestatic serum in vitro.Methods Whole bone marrow cells of rats cultured in routine medium were replaced with con-ditioning selection media containing eholestatic sera of different concentrations after they attached to the plates.The optimal concentration of cholestatic serum was determined according to the outcome of the selected cultures.Then the selected BDLSC were induced to proliferating culture system and dif-ferentiating culture system.Each passage of the proliferated stem cells was subjected to flow cytome-try for detection of stem cell markers.The morphology and phenotypie markers of BDLSC were char-acterized using immunohistochemistry, RT-PCR and electron microscopy.The metabolic functions of differentiated cells were also determined by glycogen staining and urea assay.Results The 50 ml/L eholestatie serum was the optimal concentration for the selection of BDLSC at which BDLSC could sur-vive while the other populations of the bone marrow cells could not.The purified BDLSC could prolif-erate for 6 passages and maintained stable markers in our proliferating system.When the culture sys-tem changed to differentiating system, hepatocyte-like colony-forming units (HCFU) were formed.HCFU expressed markers of embryonic hepatoeytes (AFP, albumin and cytokeratin 8/18), biliary cells (cytokeratin 19), hepatocyte functional proteins (transthyretin and eytoehrome P450-2b1), and hepatocyte nuclear factors (HNF-1α and HNF-3β).They also had glycogen storage and urea synthesis functions, two of the critical features of hepatocytes.Conclusion BDLSC can be selected directly from whole bone marrow cells and pure BDLSC can also proliferate for 6 passages.The differentiated cells have hepatocyte-like phenotype and function.BDLSC will he a new way to provide a readily avail-able alternate source of cells for clinical hepatocyte therapy.  相似文献   

15.
Objective To explore the feasibility of direct separation, selective proliferation and differentiation of BDLSC from hone marrow cells with culture systems containing cholestatic serum in vitro.Methods Whole bone marrow cells of rats cultured in routine medium were replaced with con-ditioning selection media containing eholestatic sera of different concentrations after they attached to the plates.The optimal concentration of cholestatic serum was determined according to the outcome of the selected cultures.Then the selected BDLSC were induced to proliferating culture system and dif-ferentiating culture system.Each passage of the proliferated stem cells was subjected to flow cytome-try for detection of stem cell markers.The morphology and phenotypie markers of BDLSC were char-acterized using immunohistochemistry, RT-PCR and electron microscopy.The metabolic functions of differentiated cells were also determined by glycogen staining and urea assay.Results The 50 ml/L eholestatie serum was the optimal concentration for the selection of BDLSC at which BDLSC could sur-vive while the other populations of the bone marrow cells could not.The purified BDLSC could prolif-erate for 6 passages and maintained stable markers in our proliferating system.When the culture sys-tem changed to differentiating system, hepatocyte-like colony-forming units (HCFU) were formed.HCFU expressed markers of embryonic hepatoeytes (AFP, albumin and cytokeratin 8/18), biliary cells (cytokeratin 19), hepatocyte functional proteins (transthyretin and eytoehrome P450-2b1), and hepatocyte nuclear factors (HNF-1α and HNF-3β).They also had glycogen storage and urea synthesis functions, two of the critical features of hepatocytes.Conclusion BDLSC can be selected directly from whole bone marrow cells and pure BDLSC can also proliferate for 6 passages.The differentiated cells have hepatocyte-like phenotype and function.BDLSC will he a new way to provide a readily avail-able alternate source of cells for clinical hepatocyte therapy.  相似文献   

16.
Objective To explore the feasibility of direct separation, selective proliferation and differentiation of BDLSC from hone marrow cells with culture systems containing cholestatic serum in vitro.Methods Whole bone marrow cells of rats cultured in routine medium were replaced with con-ditioning selection media containing eholestatic sera of different concentrations after they attached to the plates.The optimal concentration of cholestatic serum was determined according to the outcome of the selected cultures.Then the selected BDLSC were induced to proliferating culture system and dif-ferentiating culture system.Each passage of the proliferated stem cells was subjected to flow cytome-try for detection of stem cell markers.The morphology and phenotypie markers of BDLSC were char-acterized using immunohistochemistry, RT-PCR and electron microscopy.The metabolic functions of differentiated cells were also determined by glycogen staining and urea assay.Results The 50 ml/L eholestatie serum was the optimal concentration for the selection of BDLSC at which BDLSC could sur-vive while the other populations of the bone marrow cells could not.The purified BDLSC could prolif-erate for 6 passages and maintained stable markers in our proliferating system.When the culture sys-tem changed to differentiating system, hepatocyte-like colony-forming units (HCFU) were formed.HCFU expressed markers of embryonic hepatoeytes (AFP, albumin and cytokeratin 8/18), biliary cells (cytokeratin 19), hepatocyte functional proteins (transthyretin and eytoehrome P450-2b1), and hepatocyte nuclear factors (HNF-1α and HNF-3β).They also had glycogen storage and urea synthesis functions, two of the critical features of hepatocytes.Conclusion BDLSC can be selected directly from whole bone marrow cells and pure BDLSC can also proliferate for 6 passages.The differentiated cells have hepatocyte-like phenotype and function.BDLSC will he a new way to provide a readily avail-able alternate source of cells for clinical hepatocyte therapy.  相似文献   

17.
Objective To explore the feasibility of direct separation, selective proliferation and differentiation of BDLSC from hone marrow cells with culture systems containing cholestatic serum in vitro.Methods Whole bone marrow cells of rats cultured in routine medium were replaced with con-ditioning selection media containing eholestatic sera of different concentrations after they attached to the plates.The optimal concentration of cholestatic serum was determined according to the outcome of the selected cultures.Then the selected BDLSC were induced to proliferating culture system and dif-ferentiating culture system.Each passage of the proliferated stem cells was subjected to flow cytome-try for detection of stem cell markers.The morphology and phenotypie markers of BDLSC were char-acterized using immunohistochemistry, RT-PCR and electron microscopy.The metabolic functions of differentiated cells were also determined by glycogen staining and urea assay.Results The 50 ml/L eholestatie serum was the optimal concentration for the selection of BDLSC at which BDLSC could sur-vive while the other populations of the bone marrow cells could not.The purified BDLSC could prolif-erate for 6 passages and maintained stable markers in our proliferating system.When the culture sys-tem changed to differentiating system, hepatocyte-like colony-forming units (HCFU) were formed.HCFU expressed markers of embryonic hepatoeytes (AFP, albumin and cytokeratin 8/18), biliary cells (cytokeratin 19), hepatocyte functional proteins (transthyretin and eytoehrome P450-2b1), and hepatocyte nuclear factors (HNF-1α and HNF-3β).They also had glycogen storage and urea synthesis functions, two of the critical features of hepatocytes.Conclusion BDLSC can be selected directly from whole bone marrow cells and pure BDLSC can also proliferate for 6 passages.The differentiated cells have hepatocyte-like phenotype and function.BDLSC will he a new way to provide a readily avail-able alternate source of cells for clinical hepatocyte therapy.  相似文献   

18.
Objective To explore the feasibility of direct separation, selective proliferation and differentiation of BDLSC from hone marrow cells with culture systems containing cholestatic serum in vitro.Methods Whole bone marrow cells of rats cultured in routine medium were replaced with con-ditioning selection media containing eholestatic sera of different concentrations after they attached to the plates.The optimal concentration of cholestatic serum was determined according to the outcome of the selected cultures.Then the selected BDLSC were induced to proliferating culture system and dif-ferentiating culture system.Each passage of the proliferated stem cells was subjected to flow cytome-try for detection of stem cell markers.The morphology and phenotypie markers of BDLSC were char-acterized using immunohistochemistry, RT-PCR and electron microscopy.The metabolic functions of differentiated cells were also determined by glycogen staining and urea assay.Results The 50 ml/L eholestatie serum was the optimal concentration for the selection of BDLSC at which BDLSC could sur-vive while the other populations of the bone marrow cells could not.The purified BDLSC could prolif-erate for 6 passages and maintained stable markers in our proliferating system.When the culture sys-tem changed to differentiating system, hepatocyte-like colony-forming units (HCFU) were formed.HCFU expressed markers of embryonic hepatoeytes (AFP, albumin and cytokeratin 8/18), biliary cells (cytokeratin 19), hepatocyte functional proteins (transthyretin and eytoehrome P450-2b1), and hepatocyte nuclear factors (HNF-1α and HNF-3β).They also had glycogen storage and urea synthesis functions, two of the critical features of hepatocytes.Conclusion BDLSC can be selected directly from whole bone marrow cells and pure BDLSC can also proliferate for 6 passages.The differentiated cells have hepatocyte-like phenotype and function.BDLSC will he a new way to provide a readily avail-able alternate source of cells for clinical hepatocyte therapy.  相似文献   

19.
Objective To explore the feasibility of direct separation, selective proliferation and differentiation of BDLSC from hone marrow cells with culture systems containing cholestatic serum in vitro.Methods Whole bone marrow cells of rats cultured in routine medium were replaced with con-ditioning selection media containing eholestatic sera of different concentrations after they attached to the plates.The optimal concentration of cholestatic serum was determined according to the outcome of the selected cultures.Then the selected BDLSC were induced to proliferating culture system and dif-ferentiating culture system.Each passage of the proliferated stem cells was subjected to flow cytome-try for detection of stem cell markers.The morphology and phenotypie markers of BDLSC were char-acterized using immunohistochemistry, RT-PCR and electron microscopy.The metabolic functions of differentiated cells were also determined by glycogen staining and urea assay.Results The 50 ml/L eholestatie serum was the optimal concentration for the selection of BDLSC at which BDLSC could sur-vive while the other populations of the bone marrow cells could not.The purified BDLSC could prolif-erate for 6 passages and maintained stable markers in our proliferating system.When the culture sys-tem changed to differentiating system, hepatocyte-like colony-forming units (HCFU) were formed.HCFU expressed markers of embryonic hepatoeytes (AFP, albumin and cytokeratin 8/18), biliary cells (cytokeratin 19), hepatocyte functional proteins (transthyretin and eytoehrome P450-2b1), and hepatocyte nuclear factors (HNF-1α and HNF-3β).They also had glycogen storage and urea synthesis functions, two of the critical features of hepatocytes.Conclusion BDLSC can be selected directly from whole bone marrow cells and pure BDLSC can also proliferate for 6 passages.The differentiated cells have hepatocyte-like phenotype and function.BDLSC will he a new way to provide a readily avail-able alternate source of cells for clinical hepatocyte therapy.  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号